Clinical Trial Update: Beta-Blocker Evaluation in Survival Trial (BEST) [Phase 3]

View source ↗

Summary

Phase 3 BEST trial evaluating a beta-blocker for survival in cardiovascular disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases
• Heart Failure

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Cardiovascular Diseases, Heart Diseases | Phase 3 | Status: COMPLETED